Building New Approach Methodologies (NAMs) and Complex In Vitro Assays
Learn how Lonza’s primary human cells, media, and reagents support advanced in vitro models for drug discovery, toxicity testing, and reducing animal use.
The Hidden Variable in Your Intestinal Organoids: Enhancing Differentiation for a More Predictive Model
On June 4, 2025, Dr. Martin Stahl led a webinar exploring how cellular composition affects organoid performance in drug response and toxicity assays. He also introduced IntestiCult™ Plus Organoid Growth Medium, a next-generation organoid medium that supports simultaneous expansion and differentiation of intestinal organoids. Below are answers to audience questions from the session, edited for brevity and clarity.
The Hidden Variable in Your Intestinal Organoids: Enhancing Differentiation for a More Predictive Model
Are you confident that your intestinal organoid models contain the right cell types to generate predictive, reproducible, and translatable results?
Considerations in Tissue Acquisition and Characterization for the Development of Long-Term Tumoroid Models
Join experts from Discovery Life Science as they explore cutting-edge 3D tumor models and their potential to accelerate cancer research and development.
Industry Insights with Bas Trietsch and STEMCELL Technologies
Dr. Bas Trietsch and Dr. Jenna Moccia discuss stem cell-based models and organ-on-a-chip systems in this episode of Industry Insights.
Industry Insights with Bas Trietsch and STEMCELL Technologies
Drs. Jenna Moccia and Bas Trietsch explore how stem cell-based models are transforming drug discovery and preclinical research.
Intestinal Toxicity Assessment with Patient-Derived Organoids
Dr. Martin Stahl describes the use of patient-derived intestinal organoids to assess the toxicity of potential therapeutic compounds and study barrier function in a human-specific model system.
